State of Wisconsin Investment Board’s Kezar Life Sciences KZR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-7,218
Closed -$226K 2445
2023
Q1
$226K Buy
7,218
+2,068
+40% +$120K ﹤0.01% 2208
2022
Q4
$363K Buy
5,150
+745
+17% +$55.2K ﹤0.01% 2026
2022
Q3
$379K Buy
4,405
+3,379
+329% +$328K ﹤0.01% 2108
2022
Q2
$85K Sell
1,026
-3,594
-78% -$317K ﹤0.01% 2647
2022
Q1
$768K Sell
4,620
-2,600
-36% -$373K ﹤0.01% 1699
2021
Q4
$1.21M Buy
7,220
+2,910
+68% +$329K ﹤0.01% 1394
2021
Q3
$372K Sell
4,310
-210
-5% -$13.9K ﹤0.01% 1777
2021
Q2
$245K Sell
4,520
-1,020
-18% -$57.9K ﹤0.01% 2012
2021
Q1
$330K Buy
5,540
+180
+3% +$10.5K ﹤0.01% 1785
2020
Q4
$280K Buy
5,360
+1,200
+29% +$66.8K ﹤0.01% 1887
2020
Q3
$201K Buy
4,160
+2,380
+134% +$114K ﹤0.01% 1911
2020
Q2
$92K Buy
+1,780
New +$89.8K ﹤0.01% 1653
2019
Q3
Sell
-1,830
Closed -$141K 1567
2019
Q2
$141K Buy
+1,830
New +$285K ﹤0.01% 1509

Other funds holding KZR

State of Wisconsin Investment Board's KZR Position: Q2 2023 in Review

State of Wisconsin Investment Board sold out of Kezar Life Sciences (KZR) in Q2 2023, closing a stake of 7,218 shares — an estimated $226K sold.

State of Wisconsin Investment Board first reported a position in KZR in Q2 2019 and held it in 13 quarters. The position peaked at $1.21M in Q4 2021. 104 funds tracked by Wall St. Rank hold KZR as of Q2 2023.

  • State of Wisconsin Investment Board reported no remaining Kezar Life Sciences position as of Q2 2023 after selling out during the quarter.
  • State of Wisconsin Investment Board sold 7,218 Kezar Life Sciences shares in Q2 2023, an estimated $226K.
  • State of Wisconsin Investment Board first reported a position in Kezar Life Sciences in Q2 2019 and held it in 13 quarters.
  • State of Wisconsin Investment Board's Kezar Life Sciences position peaked at $1.21M in Q4 2021.
  • 104 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2023.

Based on State of Wisconsin Investment Board's 13F filing for Q2 2023, filed 14 Aug 2023.